Another study on colorectal cancer found that ER-phagy mediated by FAM134B can reduce UPR induced by treatment drug brigatinib, thus promoting the survival of cancer cells, while knockdown of FAM134B can increase the sensitivity of colorectal cancer to brigatinib [6]. The gene discussed is RETREG1; the disease is colorectal cancer.